Does nicotinic acid (niacin) lower blood pressure?

International Journal of Clinical Practice

Volumn 63, Issue 1, 2009, Pages 151-159

  Bays, H E ^a   Rader, D J ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Institute for Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; LAROPIPRANT; NICOTINIC ACID; PLACEBO; SELENIUM; SIMVASTATIN;

ACUTE DRUG ADMINISTRATION; BLOOD PRESSURE REGULATION; CHRONOTROPISM; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG MECHANISM; FLUSHING; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; NIACIN;

EID: 57649202648     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01934.x     Document Type: Review

References (48)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955 54 : 558 9.
2. Maccubbin DL, Sirah W, Betteridge A et al. Lipid-altering efficacy and tolerability profile of extended release niacin/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia (abstract). Eur Heart J 2007 28 : 108.
3. Bays H, Maccubbin D, Meehan A, Kuznetsova O, Mitchel Y, Paolini JP. Blood Pressure-Lowering Effect of ER Niacin and ER Niacin/Laropiprant in Dyslipidemic Patients. Presented at: American College of Cardiology, 57th Annual Scientific Sessions; 29 March-1 April 2008, Chicago, IL.
4. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987 257 : 3233 40.
5. Blankenhorn DH, Azen SP, Crawford DW et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991 83 : 438 47.
6. Blankenhorn DH, Selzer RH, Crawford DW et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993 88 : 20 8.
7. Blankenhorn DH, Azen SP, Kramsch DM et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993 119 : 969 76.
8. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 345 : 1583 92.
9. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990 323 : 1289 98.
10. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 8 : 1245 55.
11. Canner PL, Furberg CD, Terrin ML et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005 95 : 254 7.
12. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006 97 : 477 9.
13. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988 223 : 405 18.
14. Cashin-Hemphill L, Mack WJ, Pogoda JM et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990 264 : 3013 7.
15. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990 264 : 3007 12.
16. Mack WJ, Selzer RH, Hodis HN et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993 24 : 1779 83.
17. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 7.
18. Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005 142 : 95 104.
19. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008 83 : 470 8.
20. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007 18 : 415 20.
21. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007 99 : 22C 31C.
22. Prousky J, Seely D. The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr J 2005 4 : 3.
23. Abbott Laboratories. Advicor® (niacin extended-release/lovastatin tablets). http://www.rxabbott.com/pdf/advicor.pdf (accessed January 2008), North Chicago, IL, 2007.
24. Abbott Laboratories. Niaspan® tablets (niacin extended-release tablets). http://www.rxabbott.com/pdf/niaspan.pdf (accessed January 2008), North Chicago, IL, 2007.
25. Gadegbeku CA, Dhandayuthapani A, Shrayyef MZ et al. Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. Am J Hypertens 2003 16 : 67 71.
26. Kelly JJ, Lawson JA, Campbell LV et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 2000 14 : 567 72.
27. McVeigh GE. Arterial compliance in hypertension and diabetes mellitus. Am J Nephrol 1996 16 : 217 22.
28. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998 31 : 68 72.
29. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979 57 : 114 7.
30. Nye ER, Buchanan H. Short-term effect of nicotinic acid on plasma level and turnover of free fatty acids in sheep and man. J Lipid Res 1969 10 : 193 6.
31. Stern RH, Spence JD, Freeman DJ et al. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 1991 50 : 66 70.
32. Wahlberg G, Walldius G, Efendic S. Effects of nicotinic acid on glucose tolerance and glucose incorporation into adipose tissue in hypertriglyceridaemia. Scand J Clin Lab Invest 1992 52 : 537 45.
33. Wang W, Basinger A, Neese RA et al. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab 2000 279 : E50 9.
34. Gunderson K, Demissianos HV. The effects of 5-methylpyrazole-3-carboxylic acid (U-19, 425) and nicotinic acid (NA) on free fatty acids (FFAs), triglycerides (TG) and cholesterol in man. Adv Exp Med Biol 1969 4 : 213 26.
35. Bays HE, Gonzalez-Campoy JM, Bray GA et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Exp Rev Cardiovasc Ther 2008 6 : 343 68.
36. Vega GL, Cater NB, Meguro S, Grundy SM. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005 95 : 1309 13.
37. Svedmyr N, Harthon L, Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther 1969 10 : 559 70.
38. Shibasaki M, Davis SL, Cui J et al. Neurally mediated vasoconstriction is capable of decreasing skin blood flow during orthostasis in the heat-stressed human. J Physiol 2006 575 : 953 9.
39. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975 231 : 360 81.
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
41. 2 receptor subtype 1. Clin Pharmacol Ther 2007 81 : 849 57.
42. 2 receptor antagonist. Clin Pharmacol Ther 2008 83 : 840 7.
43. Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008 101 : 625 30.
44. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005 115 : 3400 3.
45. Lupattelli G, Marchesi S, Lombardini R et al. Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipidemia. Metabolism 2003 52 : 1191 5.
46. Lind L. Vasodilation in resistance arteries is related to the apolipoprotein B/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 2007 190 : 378 84.
47. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006 98 : 1352 64.
48. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002 89 : 672 8.